<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39374379</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation></Journal><ArticleTitle>Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score-adjusted retrospective cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dkae351</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkae351</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The effectiveness of the early treatment for antiviral agents in SARS-CoV-2 infection is closely related to patient comorbidities. Data on effectiveness in immunocompromised patients are limited, with reports involving highly heterogeneous and not well-defined populations. We aimed to assess the effectiveness of treatment in reducing hospitalizations in a real-world cohort of severely immunocompromised COVID-19 outpatients.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We conducted a multicentre, retrospective, observational cohort study of immunocompromised outpatients attended in infectious diseases departments from 1 January to 31 December 2022. Propensity score matching (PSM) multivariable logistic regression models were used to estimate the adjusted odds ratio [(aOR, 95% confidence interval (CI)] for the association between antiviral prescription and outcome (COVID-19-related hospitalization up to Day 90).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 746 immunocompromised outpatients with confirmed SARS-CoV-2 infection. After eligibility criteria and PSM, a total of 410 patients were analysed: 205 receiving treatment (remdesivir, sotrovimab or nirmatrelvir/ritonavir) and 205 matched controls. Fifty-two patients required at least one COVID-19-related hospitalization 8 (3.9%) versus 44 (21.5%) in the antiviral and matched control cohorts, respectively. There were 13 deaths at 90 days, of which only 4 were COVID-19-related and none in the antiviral treatment group. After adjustment for residual confounders, the use of early therapy was associated with a protective effect on the risk of hospitalization [aOR 0.13 (0.05-0.29)], as was the use of biological immunomodulators [aOR 0.27 (0.10-0.74)], whereas chronic obstructive pulmonary disease [aOR 4.65 (1.09-19.69)] and anti-CD20 use [aOR 2.76 (1.31-5.81)] increased the odds.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early antiviral treatment was associated with a reduced risk of COVID-19-related hospitalization in ambulatory severely immunocompromised COVID-19 patients.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinargote-Celorio</LastName><ForeName>Héctor</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3300-5807</Identifier><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Pérez</LastName><ForeName>Óscar</ForeName><Initials>Ó</Initials><Identifier Source="ORCID">0000-0002-8670-6404</Identifier><AffiliationInfo><Affiliation>Endocrinology Department Dr. Balmis General University Hospital, Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, University Miguel Hernández of Elche, Sant Joan d'Alacant, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-De-La-Aleja</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9360-7394</Identifier><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llenas-García</LastName><ForeName>Jara</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9125-7706</Identifier><AffiliationInfo><Affiliation>Clinical Medicine Department, University Miguel Hernández of Elche, Sant Joan d'Alacant, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Service Vega Baja Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER of Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez Pérez-Crespo</LastName><ForeName>Pedro María</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-2682-6655</Identifier><AffiliationInfo><Affiliation>Clinical Unit of Infectious Diseases and Microbiology, Valme University Hospital, Sevilla, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedicine of Sevilla (IBiS), University of Sevilla, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez-Díaz</LastName><ForeName>Juan-Carlos</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-8007-5739</Identifier><AffiliationInfo><Affiliation>Clinical Medicine Department, University Miguel Hernández of Elche, Sant Joan d'Alacant, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Service, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-López</LastName><ForeName>Belén</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8532-6864</Identifier><AffiliationInfo><Affiliation>Internal Medicine Service Vega Baja Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merchante Gutiérrez</LastName><ForeName>Nicolás</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1120-8942</Identifier><AffiliationInfo><Affiliation>Clinical Unit of Infectious Diseases and Microbiology, Valme University Hospital, Sevilla, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedicine of Sevilla (IBiS), University of Sevilla, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Rincón</LastName><ForeName>José-Manuel</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-6501-9867</Identifier><AffiliationInfo><Affiliation>Clinical Medicine Department, University Miguel Hernández of Elche, Sant Joan d'Alacant, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merino</LastName><ForeName>Esperanza</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3854-4874</Identifier><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, University Miguel Hernández of Elche, Sant Joan d'Alacant, Alicante, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>15</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39374379</ArticleId><ArticleId IdType="doi">10.1093/jac/dkae351</ArticleId><ArticleId IdType="pii">7814924</ArticleId></ArticleIdList></PubmedData></PubmedArticle>